The startup develops targeted therapies for cancer treatment through drug discovery focused on tumor immunology. By enhancing the immune response against tumors, the company aims to improve the quality of life for cancer patients.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+75Founders
Product
Problem
Cancer treatment faces challenges in effectively targeting tumors while minimizing harm to healthy tissues. Traditional therapies can have broad systemic effects, leading to significant side effects and reduced quality of life for patients. There is a need for more precise and targeted approaches that can selectively enhance the body's immune response against cancer cells.
Solution
This startup is developing a new class of targeted cancer therapies that harness the power of tumor immunology. Their drug discovery efforts are focused on identifying and developing molecules that can specifically enhance the immune system's ability to recognize and destroy cancer cells. By selectively stimulating the immune response within the tumor microenvironment, the company aims to create more effective and less toxic treatments for a wide range of cancers. This approach seeks to improve patient outcomes by achieving durable tumor control while preserving overall health and well-being.
Target Audience
The primary target audience includes cancer patients, oncologists, and pharmaceutical companies seeking innovative and targeted cancer therapies.
Features
- Drug discovery platform focused on tumor immunology
- Development of targeted therapies that enhance the immune response against tumors
- Selective stimulation of the immune system within the tumor microenvironment
- Aim to create more effective and less toxic treatments for a wide range of cancers